APO Research
Talk to an analyst

APO RESEARCH · REPORT

PET Radiopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global PET Radiopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025194 pages

Choose your research edition.

Industry ResearchPET Radiopharmaceuticals Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal PET Radiopharmaceuticals Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal PET Radiopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PET Radiopharmaceuticals Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal PET Radiopharmaceuticals Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global PET Radiopharmaceuticals market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for PET Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PET Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PET Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for PET Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PET Radiopharmaceuticals include Cardinal Health Inc. (U.S.), Bayer AG (Germany), Nordion, Inc. (Canada), Mallinckrodt plc (Ireland), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), GE Healthcare (U.K.), Eczacibasi-Monrol Nuclear Products (Turkey) and Bracco Imaging S.p.A (Italy), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PET Radiopharmaceuticals market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PET Radiopharmaceuticals and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PET Radiopharmaceuticals sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PET Radiopharmaceuticals market size, projected growth trends, production technologies, key applications, and end-use industries.

PET Radiopharmaceuticals Segment by Company

Cardinal Health Inc. (U.S.)

Bayer AG (Germany)

Nordion, Inc. (Canada)

Mallinckrodt plc (Ireland)

Lantheus Medical Imaging, Inc. (U.S.)

IBA Molecular Imaging (Belgium)

GE Healthcare (U.K.)

Eczacibasi-Monrol Nuclear Products (Turkey)

Bracco Imaging S.p.A (Italy)

Advanced Accelerator Applications S.A. (France)

PET Radiopharmaceuticals Segment by Type

F-18

Ru-82

Others

PET Radiopharmaceuticals Segment by Application

Neurology

Cardiology

Oncology

Others

PET Radiopharmaceuticals Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PET Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PET Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PET Radiopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PET Radiopharmaceuticals market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PET Radiopharmaceuticals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of PET Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of PET Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. PET Radiopharmaceuticals Industry Trends Table 2. PET Radiopharmaceuticals Industry Drivers Table 3. PET Radiopharmaceuticals Industry Opportunities and Challenges Table 4. PET Radiopharmaceuticals Industry Restraints Table 5. Global PET Radiopharmaceuticals Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global PET Radiopharmaceuticals Revenue Market Share by Manufacturers (2021-2026) Table 7. Global PET Radiopharmaceuticals Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global PET Radiopharmaceuticals Sales Market Share by Manufacturers Table 9. Global PET Radiopharmaceuticals Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global PET Radiopharmaceuticals Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global PET Radiopharmaceuticals Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global PET Radiopharmaceuticals Manufacturers, Product Type & Application Table 13. Global PET Radiopharmaceuticals Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global PET Radiopharmaceuticals by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of F-18 Table 17. Major Manufacturers of Ru-82 Table 18. Major Manufacturers of Others Table 19. Global PET Radiopharmaceuticals Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global PET Radiopharmaceuticals Sales by Type (2021-2026) & (K Units) Table 21. Global PET Radiopharmaceuticals Sales by Type (2027-2032) & (K Units) Table 22. Global PET Radiopharmaceuticals Sales Market Share by Type (2021-2026) Table 23. Global PET Radiopharmaceuticals Sales Market Share by Type (2027-2032) Table 24. Global PET Radiopharmaceuticals Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global PET Radiopharmaceuticals Revenue by Type (2021-2026) & (K Units) Table 26. Global PET Radiopharmaceuticals Revenue by Type (2027-2032) & (K Units) Table 27. Global PET Radiopharmaceuticals Revenue Market Share by Type (2021-2026) Table 28. Global PET Radiopharmaceuticals Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Neurology Table 30. Major Manufacturers of Cardiology Table 31. Major Manufacturers of Oncology Table 32. Major Manufacturers of Others Table 33. Global PET Radiopharmaceuticals Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global PET Radiopharmaceuticals Sales by Application (2021-2026) & (K Units) Table 35. Global PET Radiopharmaceuticals Sales by Application (2027-2032) & (K Units) Table 36. Global PET Radiopharmaceuticals Sales Market Share by Application (2021-2026) Table 37. Global PET Radiopharmaceuticals Sales Market Share by Application (2027-2032) Table 38. Global PET Radiopharmaceuticals Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global PET Radiopharmaceuticals Revenue by Application (2021-2026) & (K Units) Table 40. Global PET Radiopharmaceuticals Revenue by Application (2027-2032) & (K Units) Table 41. Global PET Radiopharmaceuticals Revenue Market Share by Application (2021-2026) Table 42. Global PET Radiopharmaceuticals Revenue Market Share by Application (2027-2032) Table 43. Global PET Radiopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global PET Radiopharmaceuticals Sales by Region (2021-2026) & (K Units) Table 45. Global PET Radiopharmaceuticals Sales Market Share by Region (2021-2026) Table 46. Global PET Radiopharmaceuticals Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global PET Radiopharmaceuticals Sales Forecasted Market Share by Region (2027-2032) Table 48. North America PET Radiopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America PET Radiopharmaceuticals Sales by Country (2021-2026) & (K Units) Table 50. North America PET Radiopharmaceuticals Sales by Country (2027-2032) & (K Units) Table 51. Europe PET Radiopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe PET Radiopharmaceuticals Sales by Country (2021-2026) & (K Units) Table 53. Europe PET Radiopharmaceuticals Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific PET Radiopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific PET Radiopharmaceuticals Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific PET Radiopharmaceuticals Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa PET Radiopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa PET Radiopharmaceuticals Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa PET Radiopharmaceuticals Sales by Country (2027-2032) & (K Units) Table 60. Global PET Radiopharmaceuticals Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global PET Radiopharmaceuticals Revenue by Region (2021-2026) & (US$ Million) Table 62. Global PET Radiopharmaceuticals Revenue by Region (2027-2032) & (US$ Million) Table 63. Global PET Radiopharmaceuticals Revenue Market Share by Region (2021-2026) Table 64. Global PET Radiopharmaceuticals Revenue Market Share by Region (2027-2032) Table 65. Cardinal Health Inc. (U.S.) Company Information Table 66. Cardinal Health Inc. (U.S.) Business Overview Table 67. Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio Table 69. Cardinal Health Inc. (U.S.) Recent Development Table 70. Bayer AG (Germany) Company Information Table 71. Bayer AG (Germany) Business Overview Table 72. Bayer AG (Germany) PET Radiopharmaceuticals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Bayer AG (Germany) PET Radiopharmaceuticals Product Portfolio Table 74. Bayer AG (Germany) Recent Development Table 75. Nordion, Inc. (Canada) Company Information Table 76. Nordion, Inc. (Canada) Business Overview Table 77. Nordion, Inc. (Canada) PET Radiopharmaceuticals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Nordion, Inc. (Canada) PET Radiopharmaceuticals Product Portfolio Table 79. Nordion, Inc. (Canada) Recent Development Table 80. Mallinckrodt plc (Ireland) Company Information Table 81. Mallinckrodt plc (Ireland) Business Overview Table 82. Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Product Portfolio Table 84. Mallinckrodt plc (Ireland) Recent Development Table 85. Lantheus Medical Imaging, Inc. (U.S.) Company Information Table 86. Lantheus Medical Imaging, Inc. (U.S.) Business Overview Table 87. Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio Table 89. Lantheus Medical Imaging, Inc. (U.S.) Recent Development Table 90. IBA Molecular Imaging (Belgium) Company Information Table 91. IBA Molecular Imaging (Belgium) Business Overview Table 92. IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Product Portfolio Table 94. IBA Molecular Imaging (Belgium) Recent Development Table 95. GE Healthcare (U.K.) Company Information Table 96. GE Healthcare (U.K.) Business Overview Table 97. GE Healthcare (U.K.) PET Radiopharmaceuticals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. GE Healthcare (U.K.) PET Radiopharmaceuticals Product Portfolio Table 99. GE Healthcare (U.K.) Recent Development Table 100. Eczacibasi-Monrol Nuclear Products (Turkey) Company Information Table 101. Eczacibasi-Monrol Nuclear Products (Turkey) Business Overview Table 102. Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Product Portfolio Table 104. Eczacibasi-Monrol Nuclear Products (Turkey) Recent Development Table 105. Bracco Imaging S.p.A (Italy) Company Information Table 106. Bracco Imaging S.p.A (Italy) Business Overview Table 107. Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Product Portfolio Table 109. Bracco Imaging S.p.A (Italy) Recent Development Table 110. Advanced Accelerator Applications S.A. (France) Company Information Table 111. Advanced Accelerator Applications S.A. (France) Business Overview Table 112. Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Product Portfolio Table 114. Advanced Accelerator Applications S.A. (France) Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. PET Radiopharmaceuticals Distributors List Table 118. PET Radiopharmaceuticals Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. PET Radiopharmaceuticals Product Image Figure 2. Global PET Radiopharmaceuticals Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PET Radiopharmaceuticals Market Size (2021-2032) & (US$ Million) Figure 4. Global PET Radiopharmaceuticals Sales (2021-2032) & (K Units) Figure 5. Global PET Radiopharmaceuticals Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 PET Radiopharmaceuticals Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. F-18 Image Figure 9. Ru-82 Image Figure 10. Others Image Figure 11. Global PET Radiopharmaceuticals Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global PET Radiopharmaceuticals Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global PET Radiopharmaceuticals Sales Market Share by Type (2021-2032) Figure 14. Global PET Radiopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global PET Radiopharmaceuticals Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global PET Radiopharmaceuticals Revenue Market Share by Type (2021-2032) Figure 17. Neurology Image Figure 18. Cardiology Image Figure 19. Oncology Image Figure 20. Others Image Figure 21. Global PET Radiopharmaceuticals Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global PET Radiopharmaceuticals Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global PET Radiopharmaceuticals Sales Market Share by Application (2021-2032) Figure 24. Global PET Radiopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global PET Radiopharmaceuticals Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global PET Radiopharmaceuticals Revenue Market Share by Application (2021-2032) Figure 27. North America PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America PET Radiopharmaceuticals Sales Market Share by Country (2021-2032) Figure 29. U.S. PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe PET Radiopharmaceuticals Sales Market Share by Country (2021-2032) Figure 34. Germany PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific PET Radiopharmaceuticals Sales Market Share by Country (2021-2032) Figure 41. China PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa PET Radiopharmaceuticals Sales Market Share by Country (2021-2032) Figure 49. Brazil PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile PET Radiopharmaceuticals Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global PET Radiopharmaceuticals Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global PET Radiopharmaceuticals Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America PET Radiopharmaceuticals Revenue (2021-2032) & (US$ Million) Figure 60. North America PET Radiopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe PET Radiopharmaceuticals Revenue (2021-2032) & (US$ Million) Figure 62. Europe PET Radiopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific PET Radiopharmaceuticals Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific PET Radiopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa PET Radiopharmaceuticals Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa PET Radiopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. PET Radiopharmaceuticals Value Chain Figure 68. Manufacturing Cost Structure Figure 69. PET Radiopharmaceuticals Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • F-18
  • Ru-82
  • Others
Applications
  • Neurology
  • Cardiology
  • Oncology
  • Others
Companies covered
  • Cardinal Health Inc. (U.S.)
  • Bayer AG (Germany)
  • Nordion, Inc. (Canada)
  • Mallinckrodt plc (Ireland)
  • Lantheus Medical Imaging, Inc. (U.S.)
  • IBA Molecular Imaging (Belgium)
  • GE Healthcare (U.K.)
  • Eczacibasi-Monrol Nuclear Products (Turkey)
  • Bracco Imaging S.p.A (Italy)
  • Advanced Accelerator Applications S.A. (France)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PET Radiopharmaceuticals Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PET Radiopharmaceuticals Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global PET Radiopharmaceuticals Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global PET Radiopharmaceuticals Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global PET Radiopharmaceuticals Market Dynamics
  1. 2.1 PET Radiopharmaceuticals Industry Trends
  2. 2.2 PET Radiopharmaceuticals Industry Drivers
  3. 2.3 PET Radiopharmaceuticals Industry Opportunities and Challenges
  4. 2.4 PET Radiopharmaceuticals Industry Restraints
3 PET Radiopharmaceuticals Market by Manufacturers
  1. 3.1 Global PET Radiopharmaceuticals Revenue by Manufacturers (2021-2026)
  2. 3.2 Global PET Radiopharmaceuticals Sales by Manufacturers (2021-2026)
  3. 3.3 Global PET Radiopharmaceuticals Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global PET Radiopharmaceuticals Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PET Radiopharmaceuticals Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global PET Radiopharmaceuticals Manufacturers, Product Type & Application
  7. 3.7 Global PET Radiopharmaceuticals Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PET Radiopharmaceuticals Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PET Radiopharmaceuticals Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PET Radiopharmaceuticals Tier 1, Tier 2, and Tier 3
4 PET Radiopharmaceuticals Market by Type
  1. 4.1 PET Radiopharmaceuticals Type Introduction
  2. 4.1.1 F-18
  3. 4.1.2 Ru-82
  4. 4.1.3 Others
  5. 4.2 Global PET Radiopharmaceuticals Sales by Type
  6. 4.2.1 Global PET Radiopharmaceuticals Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global PET Radiopharmaceuticals Sales by Type (2021-2032)
  8. 4.2.3 Global PET Radiopharmaceuticals Sales Market Share by Type (2021-2032)
  9. 4.3 Global PET Radiopharmaceuticals Revenue by Type
  10. 4.3.1 Global PET Radiopharmaceuticals Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global PET Radiopharmaceuticals Revenue by Type (2021-2032)
  12. 4.3.3 Global PET Radiopharmaceuticals Revenue Market Share by Type (2021-2032)
5 PET Radiopharmaceuticals Market by Application
  1. 5.1 PET Radiopharmaceuticals Application Introduction
  2. 5.1.1 Neurology
  3. 5.1.2 Cardiology
  4. 5.1.3 Oncology
  5. 5.1.4 Others
  6. 5.2 Global PET Radiopharmaceuticals Sales by Application
  7. 5.2.1 Global PET Radiopharmaceuticals Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global PET Radiopharmaceuticals Sales by Application (2021-2032)
  9. 5.2.3 Global PET Radiopharmaceuticals Sales Market Share by Application (2021-2032)
  10. 5.3 Global PET Radiopharmaceuticals Revenue by Application
  11. 5.3.1 Global PET Radiopharmaceuticals Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global PET Radiopharmaceuticals Revenue by Application (2021-2032)
  13. 5.3.3 Global PET Radiopharmaceuticals Revenue Market Share by Application (2021-2032)
6 Global PET Radiopharmaceuticals Sales by Region
  1. 6.1 Global PET Radiopharmaceuticals Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PET Radiopharmaceuticals Sales by Region (2021-2032)
  3. 6.2.1 Global PET Radiopharmaceuticals Sales by Region (2021-2026)
  4. 6.2.2 Global PET Radiopharmaceuticals Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PET Radiopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America PET Radiopharmaceuticals Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe PET Radiopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe PET Radiopharmaceuticals Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific PET Radiopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific PET Radiopharmaceuticals Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa PET Radiopharmaceuticals Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa PET Radiopharmaceuticals Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global PET Radiopharmaceuticals Revenue by Region
  1. 7.1 Global PET Radiopharmaceuticals Revenue by Region
  2. 7.1.1 Global PET Radiopharmaceuticals Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global PET Radiopharmaceuticals Revenue by Region (2021-2026)
  4. 7.1.3 Global PET Radiopharmaceuticals Revenue by Region (2027-2032)
  5. 7.1.4 Global PET Radiopharmaceuticals Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America PET Radiopharmaceuticals Revenue (2021-2032)
  8. 7.2.2 North America PET Radiopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe PET Radiopharmaceuticals Revenue (2021-2032)
  11. 7.3.2 Europe PET Radiopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific PET Radiopharmaceuticals Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific PET Radiopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa PET Radiopharmaceuticals Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa PET Radiopharmaceuticals Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Cardinal Health Inc. (U.S.)
  2. 8.1.1 Cardinal Health Inc. (U.S.) Company Information
  3. 8.1.2 Cardinal Health Inc. (U.S.) Business Overview
  4. 8.1.3 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
  6. 8.1.5 Cardinal Health Inc. (U.S.) Recent Developments
  7. 8.2 Bayer AG (Germany)
  8. 8.2.1 Bayer AG (Germany) Company Information
  9. 8.2.2 Bayer AG (Germany) Business Overview
  10. 8.2.3 Bayer AG (Germany) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer AG (Germany) PET Radiopharmaceuticals Product Portfolio
  12. 8.2.5 Bayer AG (Germany) Recent Developments
  13. 8.3 Nordion, Inc. (Canada)
  14. 8.3.1 Nordion, Inc. (Canada) Company Information
  15. 8.3.2 Nordion, Inc. (Canada) Business Overview
  16. 8.3.3 Nordion, Inc. (Canada) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Nordion, Inc. (Canada) PET Radiopharmaceuticals Product Portfolio
  18. 8.3.5 Nordion, Inc. (Canada) Recent Developments
  19. 8.4 Mallinckrodt plc (Ireland)
  20. 8.4.1 Mallinckrodt plc (Ireland) Company Information
  21. 8.4.2 Mallinckrodt plc (Ireland) Business Overview
  22. 8.4.3 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Product Portfolio
  24. 8.4.5 Mallinckrodt plc (Ireland) Recent Developments
  25. 8.5 Lantheus Medical Imaging, Inc. (U.S.)
  26. 8.5.1 Lantheus Medical Imaging, Inc. (U.S.) Company Information
  27. 8.5.2 Lantheus Medical Imaging, Inc. (U.S.) Business Overview
  28. 8.5.3 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
  30. 8.5.5 Lantheus Medical Imaging, Inc. (U.S.) Recent Developments
  31. 8.6 IBA Molecular Imaging (Belgium)
  32. 8.6.1 IBA Molecular Imaging (Belgium) Company Information
  33. 8.6.2 IBA Molecular Imaging (Belgium) Business Overview
  34. 8.6.3 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Product Portfolio
  36. 8.6.5 IBA Molecular Imaging (Belgium) Recent Developments
  37. 8.7 GE Healthcare (U.K.)
  38. 8.7.1 GE Healthcare (U.K.) Company Information
  39. 8.7.2 GE Healthcare (U.K.) Business Overview
  40. 8.7.3 GE Healthcare (U.K.) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GE Healthcare (U.K.) PET Radiopharmaceuticals Product Portfolio
  42. 8.7.5 GE Healthcare (U.K.) Recent Developments
  43. 8.8 Eczacibasi-Monrol Nuclear Products (Turkey)
  44. 8.8.1 Eczacibasi-Monrol Nuclear Products (Turkey) Company Information
  45. 8.8.2 Eczacibasi-Monrol Nuclear Products (Turkey) Business Overview
  46. 8.8.3 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Product Portfolio
  48. 8.8.5 Eczacibasi-Monrol Nuclear Products (Turkey) Recent Developments
  49. 8.9 Bracco Imaging S.p.A (Italy)
  50. 8.9.1 Bracco Imaging S.p.A (Italy) Company Information
  51. 8.9.2 Bracco Imaging S.p.A (Italy) Business Overview
  52. 8.9.3 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Product Portfolio
  54. 8.9.5 Bracco Imaging S.p.A (Italy) Recent Developments
  55. 8.10 Advanced Accelerator Applications S.A. (France)
  56. 8.10.1 Advanced Accelerator Applications S.A. (France) Company Information
  57. 8.10.2 Advanced Accelerator Applications S.A. (France) Business Overview
  58. 8.10.3 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Product Portfolio
  60. 8.10.5 Advanced Accelerator Applications S.A. (France) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PET Radiopharmaceuticals Value Chain Analysis
  2. 9.1.1 PET Radiopharmaceuticals Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PET Radiopharmaceuticals Production Mode & Process
  6. 9.2 PET Radiopharmaceuticals Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PET Radiopharmaceuticals Distributors
  9. 9.2.3 PET Radiopharmaceuticals Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst